Tradestie Institutional Equity Comparison Engine

CVM vs CGON โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGON Overall Edge

CGON Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CG Oncology, Inc. Common stock (CGON) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus CGON at N/M Forward P/E and -4293.5% operating margin (-3.7% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
CVM 23.0x vs CGON N/M Fwd P/E
Growth & Margin Winner CGON
Op Margin 0.0% vs -4293.5% ยท YoY -62.7% vs -3.7%
Momentum & Technical Winner CGON
1Y -77.5% vs +125.0% ยท 52W Pos 10% vs 84%
Options & Structure Winner CGON
BREAKDOWN (N/A IV) vs CONSOLIDATION (85th %ile IV)
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
1M Return -11.17%
1Y Return -77.48%
Forward P/E 23.0x
Unified AI Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
CGON NASDAQ
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.17% 1D
Market Cap $6.3B
1M Return +41.93%
1Y Return +124.96%
Forward P/E N/M
Unified AI Score
44.5 / 100 HOLD
Tech 15.0 Fund 43.0 Flow 69.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CVM -77.48% CGON +124.96% Spread: +183.11 pp (CGON Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CVM Revenue CGON Revenue CVM Op. Margin CGON Op. Margin Margin Edge
FY2011 $0M N/A -1881.0% N/A CVM
FY2012 $0M N/A -6772.3% N/A CVM
FY2013 $0M N/A -12450.1% N/A CVM
FY2014 $0M N/A -9721.4% N/A CVM
FY2023 N/A $0M N/A -27180.9% CGON
FY2024 N/A $0M N/A -10067.3% CGON
FY2025 N/A $0M N/A -4722.1% CGON

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CVM (4) vs CGON (5)
Institutional Metric CVM CGON Criterion Row Winner
Market Capitalization Scale $20.9M $6.3B Larger Scale CGON
Trailing P/E Ratio Valuation 23.0x N/M Lower Multiple CVM
Forward P/E Ratio Valuation 23.0x N/M Lower Multiple CVM
Revenue Growth (YoY) Growth -62.7% -3.7% Higher Growth CGON
Operating Margin (TTM) Profitability 0.0% -4293.5% Higher Margin CVM
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -252.5% -28.3% Higher ROE CGON
52-Week Range Position Momentum 10% ($1โ€“$8) 84% ($37โ€“$94) Stronger Trend CGON
Beta / 30D Volatility Risk Regime 0.65ฮฒ ยท 120% Vol 0.75ฮฒ ยท 89% Vol Lower Realized Risk CGON
Unified Institutional Score Composite Signal 56.6 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CVM vs CGON Buy Guide
CVM BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGON CONSOLIDATION
62d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 85th %ile
IV Regime Extreme (>80th %ile)
Live CGON Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CVM nor CGON registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.